Ahead of FDA meeting, S.F. biotech’s stock dips on questions about data analysis

Ahead of a critical meeting with an FDA committee, FibroGen Inc. stock tumbled more than 30% after hours on a fresh look at data around the safety of the San Francisco company's drug to treat anemia in chronic kidney disease patients. FibroGen officials said they continue to be...

Click to view original post